ARTICLE | Clinical News
C16G2: Phase I data
September 2, 2013 7:00 AM UTC
A double-blind, dose-escalation, U.S. Phase I trial in 36 healthy volunteers showed that a single oral rinse of C16G2 led to no treatment-related, severe or serious reported adverse events. ...